A Phase 3 interventional study of Furosemide in BPH With Urinary Obstruction, BPH and Hematuria, sponsored by Northwestern University. Recruiting at 1 site in United States. Open to male participants aged 18 Years to 89 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-13.
Sponsored by Northwestern University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Hematuria with a site in United States — 5 open to participants now, 6 under way, 2 of them phase 3. Hematuria · United States.
Among the 20 studies in Hematuria with a site in United States, this one is the 7th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2023, is one of 2 in phase 3, and was the 14th registered.
67 studies on the registry are indexed under Hematuria; 16 are open to participants now.
Browse Hematuria studies →5 of the 20 studies in Hematuria with a site in United States are open now. Recruiting first, the newest first:
Geisinger Clinic · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 50+
Convergent Genomics, Inc. · Sites in United States, Puerto Rico
Ages 18+
Florian Schroeck · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 10 Hematuria studies recruiting now, 7 (70%) set no upper age limit and 1 (10%) stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 89 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 138 is above the median of 100 across 35 interventional studies indexed under Hematuria.
Median enrollment 138 across the 13 interventional studies, 1,115 across the 7 observational. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 20 have an industry lead sponsor. The 10 most frequent:
Northwestern University is the lead sponsor of 1,424 studies on the registry; 199 are open to participants now.
Of its 105 completed or terminated interventional studies of FDA-regulated products, 78 (74%) have results posted.
Northwestern University has 1 study filed under Hematuria — fewer than ten, so there is no comparison to draw.
2 of the studies in Hematuria with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06870253Pangea Laboratory LLCEvaluating Bladder CARE™, a New Non-Invasive Urine Test, for Bladder Cancer Detection in Inconclusive Cases | 2027-03 |
| NCT05646485University of Texas Southwestern Medical CenterBladder Cancer Screening Trial | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Hematuria with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Holmium Laser Enucleation of the Prostate (HoLEP) is a size-independent treatment option for benign prostatic hypertrophy (BPH) as recommended by the American Urological Association (AUA) Guidelines. Loop diuretics (furosemide) have been given historically during the morcellation portion of HoLEP to promote urine production in the post-operative setting and to minimize the impact of fluid absorption during long periods of morcellation. The intra-operative use of 20mg IV furosemide in perioperative HoLEP pathways has been propagated with the dissemination of HoLEP across North America without evidence to support its routine administration. With increasing surgical efficiency from improvements in laser and morcellator technology, the role of intra-operative furosemide is unknown. This study is designed to assess if there is a significant difference in same day discharge rates after Holmium Laser Enucleation of the Prostate (HoLEP) with and without IV furosemide. .
Holmium Laser Enucleation of the Prostate (HoLEP) is a size-independent treatment option for benign prostatic hypertrophy (BPH) as recommended by the American Urological Association (AUA) Guidelines. Loop diuretics (furosemide) have been given historically during the morcellation portion of HoLEP to promote urine production in the post-operative setting and to minimize the impact of fluid absorption during long periods of morcellation. The intra-operative use of 20mg IV furosemide in perioperative HoLEP pathways has been propagated with the dissemination of HoLEP across North America without evidence to support its routine administration.
This single-center randomized controlled trial is designed to assess if there is a significant difference in same day discharge rates after Holmium Laser Enucleation of the Prostate (HoLEP). We currently attempt to perform HoLEP as a same-day discharge (SDD) procedure, however one of the main limiting factors in SDD is hematuria. Loop diuretics (furosemide) have been administered at the time of morcellation as a part of our HoLEP pathway to increase post-operative urinary output and reduce clinically significant gross hematuria and clot-formation. The objective of our study will be to assess if SDD rates are non-inferior in those patients who do not receive furosemide diuretics versus those that do.
Patients will be randomized 1:1 to 20mg of IV lasix versus control. Patients and the surgeon/post-operative care team (fellow, residents, and nursing team) will be blinded to the treatment allocation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group of patients will receive 20mg of IV furosemide during the morcellation phase of their HoLEP.
Drug: Furosemide
This group of patients will not receive 20mg of IV furosemide during the morcellation phase of their HoLEP.
20mg of IV furosemide injection during the morcellation phase of HoLEP
Also known as: Lasix, Loop diuretic
Same-day discharge
Rate of successful same-day discharge after HoLEP
Time frame: 90-days
Same-day catheter removals
Rate of successful same-day catheter removals after HoLEP
Time frame: 90-days
Adverse medical events (hematuria)
Rate of unplanned Emergency Department (ED) visits/clinic visits related to bleeding/admission/clot evacuation
Time frame: 90-days
Adverse medical events (fluid absorption)
Rate of transurethral resection (TUR) syndrome, vision changes, seizure, hyponatremia, electrolyte abnormality
Time frame: 90-days
Duration of post-operative hematuria
(days)
Time frame: 90-days
Difference in operative efficiency (enucleation, morcellation, and overall)
(minutes/gram)
Time frame: 90-days
Length of hospital stay
(hours)
Time frame: 90-days
Overall complications
Clavien-Dindo Classification
Time frame: 90-days
Plan to share: No
Ran from Mar 2023 to primary completion in Jun 2023, 3 months.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Furosemide